Drug Trial Radar · NCT05103423
Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
Last checked: Nov 19, 2026Latest source record: Mar 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Jun 24, 2021
Primary completion
Jul 7, 2023
Study completion Jul 7, 2023
Sponsor
- Lead sponsor
- Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to explore the safety and efficacy of treatment with BDB-001 Injection in adults with moderate to severe hidradenitis suppurativa (HS).
Conditions
- Hidradenitis Suppurativa
Interventions
BDB-001 InjectionDrug
Multiple IV infusions of BDB-001 Injection diluted in sodium chloride
PlaceboDrug
Multiple IV infusions of Placebo Injection diluted in sodium chloride
PlaceboDrug
Multiple IV infusions of Placebo Injection diluted in sodium chloride
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.Time frame: Week 8
- Number of Participants developing anti-BDB-001 antibodies.Time frame: Week 8
- Area under the plasma concentration versus time curve (AUC) of BDB-001 Assessment of pharmacokinetic parameters.Time frame: Week 8
- Peak Plasma Concentration (Cmax) of BDB-001and time to reach Cmax Assessment of pharmacokinetic parameters.Time frame: Week 8
- Minimal Plasma Concentration (Cmin) of BDB-001 Assessment of pharmacokinetic parameters.Time frame: Week 8
- Terminal phase half-life Assessment of pharmacokinetic parameters.Time frame: Week 8
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, Beijing Municipality, China
Plastic Surgery Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Union Hospital Tongji Medical College Huazong University of Science and Technology
Wuhan, Hubei, China
Xiangya Hospital, Central South University
Changsha, Hunan, China
Chinese Academy of Medical Sciences and Peking Union Medical College
Nanjing, Jiangsu, China
The First Hospital of Jilin Universitv
Changchun, Jilin, China
The First Hospital of China Medical University
Shenyang, Liaoning, China
The First Affiliated Hospital of Air Force Medical University
Xi'an, Shaanxi, China
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
Qilu Hospital of Shandong University
Jinan, Shandong, China
Huashan Hospital of Fudan University
Shanghai, Shanghai Municipality, China
Shanghai Skin Disease Hospital
Shanghai, Shanghai Municipality, China
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.